Literature DB >> 8528701

Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord.

G Pugh1, M E Abood, S P Welch.   

Abstract

Intrathecal pretreatment of mice with an antisense oligodeoxynucleotide directed against the kappa-1 receptor significantly reduced the antinociceptive effects of the kappa receptor agonist U50,488 as well as delta 9-THC, the major psychoactive ingredient found in cannabis. A mismatched oligodeoxynucleotide which contained four switched bases did not block the antinociception produced by U50,488 or delta 9-THC. Furthermore, kappa-1 antisense did not alter the antinociceptive effects of either the mu receptor-selective opioid DAMGO, or the delta receptor-selective opioid DPDPE. By using kappa-1 antisense, we were able to demonstrate that an interaction occurs between the cannabinoids and opioids in the spinal cord.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528701     DOI: 10.1016/0006-8993(95)00560-d

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

Review 1.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

2.  Additive antinociceptive effects of mixtures of the κ-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats.

Authors:  David R Maguire; Charles P France
Journal:  Behav Pharmacol       Date:  2016-02       Impact factor: 2.293

3.  Attenuation of cannabinoid-induced inhibition of medullary dorsal horn neurons by a kappa-opioid receptor antagonist.

Authors:  Akiko Okada-Ogawa; Masayuki Kurose; Ian D Meng
Journal:  Brain Res       Date:  2010-08-31       Impact factor: 3.252

4.  The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.

Authors:  George R Kracke; Sean P Stoneking; Joshua M Ball; Brandon M Tilghman; Carmen C Washington; Katherine A Hotaling; Joel O Johnson; Joseph D Tobias
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-25       Impact factor: 3.000

5.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Authors:  J Manzanares; Md Julian; A Carrascosa
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.